Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bavarian Nordic A/S

http://www.bavarian-nordic.com/

Latest From Bavarian Nordic A/S

Bavarian Nordic To Raise $250m For Phase III RSV Vaccine Study

The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022

Vaccines Financing

Coronavirus Notebook: EMA OKs Roche's Tocilizumab For Severe COVID-19, Bavarian Nordic Reports ‘Positive’ Booster Results

The European Commission is to replace its COVID-19 vaccine export authorization system with a monitoring scheme, and the European Medicines Agency has confirmed the risk of myocarditis and pericarditis with the mRNA vaccines. The WHO and other bodies have called for better vaccine donation practices in Africa.

Europe International

CDC Panel Stops Shy Of Universal Adult Hepatitis B Vaccine Recommendation

ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.

Advisory Committees Vaccines

Bavarian Nordic Seeks Partner After RSV Jab Generates Glowing Phase II Data

Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register